A Prospective Observational Cohort Study for Newly Diagnosed Osteosarcoma Patients in the UK: ICONIC Study Initial Results

• Published in: Cancers Vol. 16; no. 13; p. 2351
• Main Authors: Childs, Alexa, Gerrand, Craig, Brennan, Bernadette, Young, Robin, Rankin, Kenneth S, Parry, Michael, Stevenson, Jonathan, Flanagan, Adrienne M, Taylor, Rachel M, Fern, Lorna, Heymann, Dominique, Vance, Filipa, Sherriff, Jenny, Singh, Saurabh, Begum, Rubina, Forsyth, Sharon L, Reczko, Krystyna, Sparksman, Kate, Wilson, William, Strauss, Sandra J
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.06.2024; MDPI
• Subjects: Biomarkers; Biopsy; Bone cancer; Cancer therapies; Chemotherapy; Clinical outcomes; Clinical trials; Cohort analysis; Collaboration; Data collection; Developmental stages; DNA methylation; Drug dosages; Feasibility studies; Genomes; Hypotheses; Life Sciences; Medical history; Medical prognosis; Medical research; Metastasis; Osteosarcoma; Pathology; Patients; Radiation therapy; Recruitment; Registration; Sarcoma; Standard of care; Surgery; Toxicity; United Kingdom > UK; England; treatment; observational; quality of life; biomarkers; osteosarcoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16132351

There has been little change to the standard treatment for osteosarcoma (OS) over the last 25 years and there is an unmet need to identify new biomarkers and novel therapeutic approaches if outcomes are to improve. Furthermore, there is limited evidence on the impact of OS treatment on patient-reported outcomes (PROs). ICONIC (Improving Outcomes through Collaboration in Osteosarcoma; NCT04132895) is a prospective observational cohort study recruiting newly diagnosed OS patients across the United Kingdom (UK) with matched longitudinal collection of clinical, biological, and PRO data. During Stage 1, which assessed the feasibility of recruitment and data collection, 102 patients were recruited at 22 sites with representation from patient groups frequently excluded in OS studies, including patients over 50 years and those with less common primary sites. The feasibility of collecting clinical and biological samples, in addition to PRO data, has been established and there is ongoing analysis of these data as part of Stage 2. ICONIC will provide a unique, prospective cohort of newly diagnosed OS patients representative of the UK patient population, with fully annotated clinical outcomes linked to molecularly characterised biospecimens, allowing for comprehensive analyses to better understand biology and develop new biomarkers and novel therapeutic approaches.